Endometrial cancer (EC) is the most common gynaecological cancer. Current treatment of EC typically includes removal of the uterus and to determine the extent of the disease (removal of fallopian tubes, ovaries \& if required a lymph node dissection (surgical staging)). While lymph node dissection may be valuable to guide the need for adjuvant treatment (chemo or radiotherapy) after surgery, it has been a topic of controversy for the last 30 years. In some patients it causes morbidity, specifically lymphoedema. This recently has been replaced with sentinel node biopsy (SNB). It requires an inj
TH BSO with SNB Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted
TH BSO without retroperitoneal node dissection Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted
Locations (sample)
Houston, Texas, United States|29.76328,-95.36327
Buenos Aires, Ciudad Autónoma de Buenos Aires (caba), Argentina|-34.61315,-58.37723
Buenos Aires, Ciudad Autónoma de Buenos Aires (caba), Argentina|-34.61315,-58.37723
Camperdown, New South Wales, Australia|-33.88965,151.17642
Liverpool, New South Wales, Australia|-33.91938,150.92588
Key Eligibility Criteria
Females, over 18 years, with histologically confirmed primary epithelial cancer of the endometrium of any cell type or uterine carcinosarcoma (mixe…
Clinically stage I disease (disease confined to body of uterus);
Eastern Cooperative Oncology Group (ECOG) performance status of ≤2;